MILLENNIUM MANAGEMENT LLC - CORBUS PHARMACEUTICALS HLDGS ownership

CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 75 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q1 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.

Quarter-by-quarter ownership
MILLENNIUM MANAGEMENT LLC ownership history of CORBUS PHARMACEUTICALS HLDGS
ValueSharesWeighting
Q3 2022$2,000
-97.7%
11,585
-96.7%
0.00%
Q2 2022$88,000
-66.5%
348,917
-29.4%
0.00%
Q1 2022$263,000
-36.5%
494,050
-26.4%
0.00%
Q4 2021$414,000
-40.0%
671,713
-0.7%
0.00%
Q3 2021$690,000
-69.7%
676,108
-45.6%
0.00%
-100.0%
Q2 2021$2,275,000
+10240.9%
1,242,977
+6849.8%
0.00%
Q4 2020$22,000
-99.5%
17,885
-96.3%
0.00%
-100.0%
Q2 2020$4,029,000
+2020.5%
480,192
+1226.1%
0.01%
Q1 2020$190,000
-96.4%
36,210
-95.2%
0.00%
-100.0%
Q2 2019$5,226,000
+2650.5%
754,061
+2659.0%
0.01%
Q1 2019$190,000
-75.0%
27,331
-79.0%
0.00%
-100.0%
Q4 2018$761,000
+233.8%
130,245
+331.4%
0.00%
Q3 2018$228,000
-70.5%
30,194
-80.3%
0.00%
-100.0%
Q2 2018$772,000
-80.7%
152,930
-72.9%
0.00%
-83.3%
Q4 2017$4,002,000
-34.8%
563,657
-34.4%
0.01%
-33.3%
Q3 2017$6,141,000
+39.3%
858,946
+22.8%
0.01%
+12.5%
Q2 2017$4,407,000
-18.1%
699,471
+7.3%
0.01%
-20.0%
Q1 2017$5,378,000
-12.7%
651,871
-10.6%
0.01%
-23.1%
Q4 2016$6,161,000
+32326.3%
729,139
+6394.5%
0.01%
Q4 2015$19,000
-50.0%
11,227
-53.6%
0.00%
Q3 2015$38,00024,2000.00%
Other shareholders
CORBUS PHARMACEUTICALS HLDGS shareholders Q1 2022
NameSharesValueWeighting ↓
Knoll Capital Management, LLC 5,045,870$1,273,0000.73%
ETF MANAGERS GROUP, LLC 7,062,485$1,787,0000.05%
Ikarian Capital, LLC 862,527$217,0000.04%
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 457,209$115,0000.02%
Platform Technology Partners 33,750$9,0000.01%
PINNACLE ASSOCIATES LTD 910,006$230,0000.01%
CJM Wealth Advisers, Ltd. 30,465$7,6830.01%
Mirae Asset Global Investments Co., Ltd. 4,029,171$1,016,0000.00%
Vident Investment Advisory, LLC 267,612$67,0000.00%
Aries Wealth Management 15,400$4,0000.00%
View complete list of CORBUS PHARMACEUTICALS HLDGS shareholders